About Dr. Bao Chunde
Dr. Bao Chunde (鲍春德) is one of China's most eminent rheumatologists and a nationally recognized authority on systemic lupus erythematosus (SLE), rheumatoid arthritis, and autoimmune disease. He serves as Director of the Department of Rheumatology and Immunology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and holds the title of Chief Physician and Professor.
Over a career spanning more than three decades, Dr. Bao has built Ruijin Hospital's Rheumatology Department into one of the most respected autoimmune disease centers in China. He is particularly renowned for his expertise in lupus nephritis, refractory autoimmune conditions, and the application of biologic and targeted therapies in rheumatic disease — areas where his contributions have shaped national clinical guidelines and influenced practice across Asia.
International patients with complex autoimmune conditions — including SLE, rheumatoid arthritis, vasculitis, and inflammatory myopathies — consistently identify Dr. Bao as one of China's top specialists for both primary treatment and second opinions on difficult or refractory cases.
Professional Positions and Affiliations
- Director, Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Past President, Chinese Rheumatology Association
- Chairman, SLE Committee, Chinese Rheumatology Association
- Editorial Board Member: Annals of the Rheumatic Diseases, Lupus, Clinical Rheumatology
- Member, European League Against Rheumatism (EULAR)
- Member, American College of Rheumatology (ACR)
- Principal Investigator, multiple national and international multicenter clinical trials in SLE and RA
Specialties and Clinical Expertise
Dr. Bao's clinical practice encompasses the full spectrum of rheumatic and autoimmune diseases, with particular depth in lupus and its systemic complications. His approach integrates the latest molecular diagnostics with individualized, treat-to-target management strategies.
- Systemic Lupus Erythematosus (SLE) — comprehensive management including lupus nephritis, neuropsychiatric lupus, hematologic lupus, and antiphospholipid syndrome; biologic therapy (belimumab, anifrolumab) and immunosuppressive protocols
- Rheumatoid Arthritis (RA) — treat-to-target protocols combining conventional DMARDs (methotrexate, leflunomide), biologics (TNF inhibitors, IL-6 inhibitors, abatacept), and JAK inhibitors; joint protection and remission maintenance
- Vasculitis — ANCA-associated vasculitis (GPA, MPA, EGPA), giant cell arteritis, Takayasu arteritis, and Behcet's disease; rituximab and cyclophosphamide-based induction protocols
- Inflammatory Myopathies — dermatomyositis, polymyositis, and anti-synthetase syndrome; including interstitial lung disease (ILD) management
- Sjogren's Syndrome — systemic manifestations, sicca symptom management, and lymphoma surveillance
- Systemic Sclerosis (Scleroderma) — skin, pulmonary, renal, and vascular complications; antifibrotic and immunosuppressive therapy
- Psoriatic Arthritis and Spondyloarthropathy — biologic therapy (IL-17 inhibitors, IL-23 inhibitors, TNF inhibitors) and small molecule therapy
- Refractory Autoimmune Disease — complex cases that have failed standard therapy; novel immunotherapy approaches including CAR-T cell therapy for severe SLE
Academic and Research Contributions
Dr. Bao Chunde has published over 280 peer-reviewed papers in leading international rheumatology journals, with a particular focus on the pathogenesis of SLE, lupus nephritis outcomes, and the optimization of biologic therapy in Chinese patients. His research on the distinct clinical and immunological features of SLE in Asian populations has been widely cited and has directly informed international treatment guidelines.
He has led landmark multicenter trials on belimumab and anifrolumab in Chinese SLE patients, contributing pivotal data that supported regulatory approval of these biologics in China. His work on lupus nephritis induction and maintenance therapy has been incorporated into both Chinese national guidelines and EULAR/ACR recommendations.
Dr. Bao is a past President of the Chinese Rheumatology Association and has chaired the SLE Committee for multiple terms, leading the development of China's national SLE management guidelines. He is a regular invited speaker at EULAR, ACR, and the Asia Pacific League of Associations for Rheumatology (APLAR) annual congresses.
In recent years, Dr. Bao has been at the forefront of exploring CAR-T cell therapy for severe, refractory SLE — a groundbreaking approach that has shown remarkable early results in patients who have failed all conventional treatments, and in which Ruijin Hospital is one of the leading centers globally.
Approach to Patient Care
Dr. Bao is known for his meticulous, patient-centered approach to complex autoimmune disease. He leads a multidisciplinary team that brings together rheumatologists, nephrologists, pulmonologists, dermatologists, and hematologists to develop comprehensive management plans for patients with multi-organ autoimmune involvement.
For international patients — many of whom arrive with longstanding diagnoses and prior treatment histories from overseas institutions — Dr. Bao takes particular care to review all available laboratory, imaging, and pathology data before forming an independent clinical opinion. His familiarity with international treatment standards (EULAR, ACR, BSR guidelines) makes him an ideal consultant for patients who have been treated abroad and are seeking expert validation or access to therapies not yet available in their home country.
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital is one of China's most prestigious academic medical centers, consistently ranked among the top hospitals nationally. The Department of Rheumatology and Immunology at Ruijin is a National Key Clinical Specialty and one of the highest-volume autoimmune disease centers in China. The department operates:
- A dedicated Lupus Nephritis Clinic with integrated nephrology support and renal biopsy capability
- A Biologic Therapy Unit administering the full range of approved biologics and small molecule therapies
- A CAR-T Cell Therapy Program for Autoimmune Disease — one of the first and most active in the world
- A Multidisciplinary Autoimmune Disease MDT meeting weekly for complex multi-organ cases
- A Clinical Trials Unit running multiple Phase II-III studies in SLE, RA, and vasculitis
Why International Patients Choose Dr. Bao Chunde
- China's leading lupus specialist — national guideline author and past President of the Chinese Rheumatology Association
- CAR-T therapy for SLE pioneer — Ruijin is one of the world's leading centers for this groundbreaking approach in refractory lupus
- Full biologic therapy access — belimumab, anifrolumab, rituximab, and all approved targeted therapies
- Asian patient population expertise — SLE presents differently in Asian patients; Dr. Bao's research specifically addresses this
- EULAR/ACR-aligned practice — familiar with international guidelines, ideal for patients transitioning from Western healthcare systems
- Second opinion authority — regularly reviews complex overseas cases for international patients
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
- Appointment Lead Time: 2–4 weeks for new patients; urgent cases may be expedited through CMCS
- Consultation Format: In-person consultation; remote pre-consultation record review available through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Medical Records: CMCS provides full translation of overseas medical records, lab results, and imaging into Chinese prior to consultation
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking consultation or treatment with Dr. Bao Chunde at Ruijin Hospital. Our services include:
- Priority appointment booking and scheduling coordination
- Medical record and laboratory result translation (English ↔ Chinese)
- Remote pre-consultation record review facilitation
- On-site interpretation during consultations and procedures
- Accommodation coordination near Ruijin Hospital
- Insurance liaison and billing support
- Post-treatment follow-up coordination with your home country rheumatologist
- Clinical trial eligibility assessment for SLE, RA, and vasculitis studies
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 commentaire